Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Liabilities and Shareholders Equity: 2014-2025

Historic Liabilities and Shareholders Equity for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $158.3 million.

  • CytomX Therapeutics' Liabilities and Shareholders Equity rose 13.87% to $158.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $552.3 million, marking a year-over-year decrease of 19.33%. This contributed to the annual value of $120.5 million for FY2024, which is 40.27% down from last year.
  • Per CytomX Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $158.3 million for Q3 2025, which was down 9.60% from $175.1 million recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Liabilities and Shareholders Equity peaked at $434.2 million during Q1 2021, and registered a low of $98.5 million during Q1 2025.
  • For the 3-year period, CytomX Therapeutics' Liabilities and Shareholders Equity averaged around $172.9 million, with its median value being $175.1 million (2025).
  • Data for CytomX Therapeutics' Liabilities and Shareholders Equity shows a peak YoY increase of 13.87% (in 2025) and a maximum YoY decrease of 46.67% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Liabilities and Shareholders Equity stood at $339.4 million in 2021, then declined by 23.13% to $260.9 million in 2022, then declined by 22.65% to $201.8 million in 2023, then tumbled by 40.27% to $120.5 million in 2024, then increased by 13.87% to $158.3 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $158.3 million for Q3 2025, versus $175.1 million for Q2 2025 and $98.5 million for Q1 2025.